GlassScriptPhysician profile
Stephanie E Tyson
NPI 1437683224
$1,636.57
in general payments reported to CMS, 2019-2025
27 companies · $975 in 2025
The $975 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $51.63 · 2023: $92.96 · 2024: $517 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $238.40 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $191.20 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $168.93 | 2024-2025 | |
| Pfizer INC. | $125.28 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $113.97 | 2025 | Fanapt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.22 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $67.39 | 2022-2025 | Iclusig, Trintellix |
| Incyte Corporation | $62.07 | 2022-2024 | Jakafi |
| Novartis Pharmaceuticals Corporation | $59.70 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.16 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $45.36 | 2023-2024 | Ojjaara |
| Lilly USA, LLC | $44.17 | 2024-2025 | Verzenio, Retevmo, Jaypirca |
| Inspire Medical Systems, INC. | $41.58 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.67 | 2025 | Jardiance |
| Sumitomo Pharma America, INC. | $34.50 | 2025 | Gemtesa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $33.42 | 2024-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $33.41 | 2024 | Opdivo |
| Seagen INC. | $25.74 | 2023 | Tukysa |
| Regeneron Healthcare Solutions, INC. | $25.15 | 2024 | Libtayo |
| Otsuka America Pharmaceutical, INC. | $24.52 | 2025 | Rexulti |
| Astellas Pharma US INC | $23.35 | 2024 | Padcev |
| Lundbeck LLC | $23.27 | 2025 | Rexulti |
| Abbott Laboratories | $22.03 | 2025 | Freestyle Libre 3 |
| Pharmaessentia USA Corporation | $21.40 | 2024 | Besremi |
| Jazz Pharmaceuticals INC. | $19.45 | 2024 | |
| Daiichi Sankyo INC. | $16.43 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Tyson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.